Pemigatinib 4.5 MG for Pancreatic Cancer

"This particular clinical trial is only enrolling patients aged 18 to 100. For context, there are 86 other trials specifically for people under 18 and 3176 studies for patients over 65 years old."

"That is correct, the information available on clinicaltrials.gov does show that this study is still looking for test subjects. The trial was first advertised on 6/14/2022 and was last updated 8/8/2022. They are currently recruiting for 20 patients from 1 site."

"Since this is a phase 2 trial, there is only some data supporting the safety of Pemigatinib 4.5 MG. Consequently, our team has given it a score of 2."

"Yes, the data on clinicaltrials.gov says that this trial is actively recruiting participants. The clinical trial was originally posted on 6/14/2022 and was last edited on 8/8/2022. The trial is enrolling 20 participants across 1 location."

"This trial is seeking 20 individuals over the age of 18 who have been diagnosed with carcinoma. In addition to meeting the age requirement, participants must also: -Be male or female-Able to provide informed consent and comply with trial procedures-Histologically or cytologically confirmed adenosquamous carcinoma of the pancreas (ASCP) -Metastatic or unresectable ASCP patients who have progressed on at least one line of therapy -FGFR gene fusion, mutation, or rearrangement as determined by standard CLIA-certified FDA-approved genomic panel"